Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Molecular Devices Announces Brand Identity for Its Newly-Formed Biologics Business Unit

Molecular Devices
Posted on: 24 Oct 18
Molecular Devices Announces Brand Identity for Its Newly-Formed Biologics Business Unit Industry-leading ForteBio brand repositioned to focus on delivering breakthroughs in early stage biologic drug development.

PR Newswire

SAN JOSE, Calif., Oct. 23, 2018

SAN JOSE, Calif., Oct. 23, 2018 /PRNewswire-PRWeb/ -- Molecular Devices LLC, a leader in protein and cell biology technologies, today announced a new, exciting brand for its recently created biologics solutions business unit. The business unit combines the industry-leading ForteBio label-free technology platform with Molecular Devices' Biologics Biotherapeutics portfolio of products, and henceforth will be known as ForteBio. It is accompanied by a new logo.

ForteBio's mission is to fast-track timelines by removing hurdles in early stage biologics development through innovative technologies and workflow solutions. Its three core values aim to remove technical hurdles and workflow bottlenecks for its customers through best-in-class, high quality products and apply scientific expertise to solving customers' research challenges through lasting partnerships.

1) CUSTOMER COMMITMENT: ForteBio's solutions enable customers to make breakthroughs faster, help them be more productive, remove their technical hurdles and unlock their workflow bottlenecks.

2) QUALITY: ForteBio's best-in-class products, technical know-how and first-class service empower our customers to be successful.

3) PARTNERSHIP: ForteBio knows the science behind its customer's research and works with them as a trusted partner to find the best solutions for their research challenges.

"We are making great progress in hitting our milestones for the newly formed biologics business unit within Molecular Devices," said Greg Milosevich, President of Molecular Devices. "We successfully defined our strategic plan earlier this summer aimed at taking market share in the fast growing early stage biologic drug R&D market and have assembled a strong commercial team to help us realize this goal. Our new brand identity and logo convey with great clarity our vision, mission and core values. With a refreshed brand, an energized team and new mission, I expect ForteBio will deliver important breakthroughs to power early stage biologic drug development."

About Molecular Devices
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics and have been adopted in over 140,000 laboratories worldwide generating over 150,000 peer reviewed publications referencing Molecular Devices in materials and methods.

Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe. For more information about the complete product portfolio, visit http://www.moleculardevices.com. To learn more about the new ForteBio brand, visit http://www.fortebio.com.

 

SOURCE Molecular Devices

PR Newswire
www.prnewswire.com

Last updated on: 24/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.